Literature DB >> 14718432

Diffuse cystic lung diseases: correlation between radiologic and functional status.

Giuseppe Paciocco1, Elisabetta Uslenghi, Achille Bianchi, Gennaro Mazzarella, Giancarlo C Roviaro, Giuseppe Vecchi, Sergio Harari.   

Abstract

BACKGROUND: High-resolution CT (HRCT) scanning plays an important role in the diagnosis of diffuse cystic lung diseases (DCLDs). However, its role in the clinical evaluation of patients affected by DCLD has not yet been well-clarified. At present, pulmonary function tests are the only methods available for the evaluation of lung impairment due to these diseases, but their sensitivity and reliability are still limited.
PURPOSE: The aim of this study was to correlate the quantitative score of cystic-aerial lesions obtained by a HRCT density mask (DM) software with pulmonary function data in DCLDs.
METHODS: Spirometry, lung volumes, diffusion capacity, arterial blood gas (ABG) analysis, 6-min walking test (6-MWT), and HRCT with DM quantitative evaluation were performed in a cohort of 25 patients (lymphangioleiomyomatosis [LAM], 13 patients; Langerhans cells histiocytosis [LCH], 12 patients). Linear regression was used for the statistical analysis. The sum and mean of the air-trapping percentages at three different levels of DM study (ie, aortic arch, left lower lobe bronchus origin, and 2 cm from the diaphragmatic muscle), and various functional parameters and exercise performance values were matched for the analysis.
RESULTS: An obstructive pattern was present in 13 patients (52%; LCH group, 8 patients; LAM group, 5 patients). A predominant restrictive pattern was detected only in three patients (12%; LCH group, two patients; LAM group, one patient). Nine patients (36%) walked < 350 m, and 14 of 23 patients (61%) had a significant decrease in arterial oxygen saturation during exercise (> 4 U). The results of DM quantitative study (sum and mean) significantly correlated with FVC (r = - 0.56; p < 0.001), FEV(1)/vital capacity (r = - 0.94; p < 0.002), midexpiratory phase of forced expiratory flow (r = - 0.84; p < 0.05), FEV(1) (r = - 0.82; p < 0.05), and diffusing capacity of the lung for carbon monoxide (r = - 0.82; p < 0.05), bronchial airway resistance (r = 0.79; p < 0.05), and distance walked on the 6-MWT (r = - 0.53; p < 0.05). No significant correlation was found with the results of ABG analysis.
CONCLUSIONS: In DCLDs, HRCT scans with quantitative assessment performed by a DM software showed a very good correlation with functional parameters. Therefore, DM could be considered, in combination with a complete functional assessment, in the initial evaluation of patients affected by DCLDs. However, further studies are needed to assess its usefulness in the follow-up of these patients.

Entities:  

Mesh:

Year:  2004        PMID: 14718432     DOI: 10.1378/chest.125.1.135

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  12 in total

Review 1.  Lymphangioleiomyomatosis: what do we know and what are we looking for?

Authors:  S Harari; O Torre; J Moss
Journal:  Eur Respir Rev       Date:  2011-03

2.  The natural history of lymphangioleiomyomatosis: markers of severity, rate of progression and prognosis.

Authors:  Angelo M Taveira-DaSilva; Gustavo Pacheco-Rodriguez; Joel Moss
Journal:  Lymphat Res Biol       Date:  2010-03       Impact factor: 2.589

3.  Randomized phase II trial of inhaled budesonide versus placebo in high-risk individuals with CT screen-detected lung nodules.

Authors:  Giulia Veronesi; Eva Szabo; Andrea Decensi; Aliana Guerrieri-Gonzaga; Massimo Bellomi; Davide Radice; Stefania Ferretti; Giuseppe Pelosi; Matteo Lazzeroni; Davide Serrano; Scott M Lippman; Lorenzo Spaggiari; Angela Nardi-Pantoli; Sergio Harari; Clara Varricchio; Bernardo Bonanni
Journal:  Cancer Prev Res (Phila)       Date:  2010-12-16

4.  Emerging clinical picture of lymphangioleiomyomatosis.

Authors:  M M Cohen; S Pollock-BarZiv; S R Johnson
Journal:  Thorax       Date:  2005-07-29       Impact factor: 9.139

5.  Clinical CT underestimation of the percentage volume occupied by cysts in patients with lymphangioleiomyomatosis.

Authors:  Thomas C Larsen; Amir M Hasani; Shirley F Rollison; Tania R Machado; Amanda M Jones; Patricia Julien-Williams; Marcus Y Chen; Joel Moss; Han Wen
Journal:  Clin Imaging       Date:  2019-11-27       Impact factor: 1.605

6.  Budesonide versus placebo in high-risk population with screen-detected lung nodules: rationale, design and methodology.

Authors:  Matteo Lazzeroni; Aliana Guerrieri-Gonzaga; Davide Serrano; Maria Clara Varricchio; Giulia Veronesi; Davide Radice; Irene Feroce; Angela Nardi-Pantoli; Scott M Lippman; Eva Szabo; Bernardo Bonanni
Journal:  Contemp Clin Trials       Date:  2010-08-16       Impact factor: 2.226

7.  Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies.

Authors:  Connie G Glasgow; Wendy K Steagall; Angelo Taveira-Dasilva; Gustavo Pacheco-Rodriguez; Xiong Cai; Souheil El-Chemaly; Marsha Moses; Thomas Darling; Joel Moss
Journal:  Respir Med       Date:  2010-07       Impact factor: 3.415

8.  Effect of a gonadotrophin-releasing hormone analogue on lung function in lymphangioleiomyomatosis.

Authors:  Sergio Harari; Roberto Cassandro; Iacopo Chiodini; Jacopo Chiodini; Angelo M Taveira-DaSilva; Joel Moss
Journal:  Chest       Date:  2007-12-10       Impact factor: 9.410

Review 9.  Lymphangioleiomyomatosis and tuberous sclerosis complex.

Authors:  Dimitrios Chorianopoulos; Grigoris Stratakos
Journal:  Lung       Date:  2008-04-12       Impact factor: 2.584

10.  Evaluation of the extent of pulmonary cysts and their association with functional variables and serum markers in lymphangioleiomyomatosis (LAM).

Authors:  Bruno Guedes Baldi; Mariana Sponholz Araujo; Carolina Salim Gonçalves Freitas; Gustavo Borges da Silva Teles; Ronaldo Adib Kairalla; Olívia Meira Dias; Daniel Antunes Silva Pereira; Suzana Pinheiro Pimenta; Carlos Roberto Ribeiro Carvalho
Journal:  Lung       Date:  2014-09-09       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.